Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.

Journal of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.

Neurology·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

Redefining Multiple Sclerosis: Toward a Biologically Driven Diagnosis.

Neurology·2026
Same author

Quality of life domains revised by people with multiple sclerosis and healthcare professionals for adaptive measure development.

PloS one·2026
Same journal

Five Issues of Artificial Intelligence in Science: Sailing the Ship of Theseus.

Annals of neurology·2026
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
Same journal

Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease.

Annals of neurology·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K

Identifying Progression in Multiple Sclerosis: New Perspectives.

Massimo Filippi1,2,3,4, Paolo Preziosa1,2, Dawn Langdon5

  • 1Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Annals of Neurology
|June 8, 2020
PubMed
Summary
This summary is machine-generated.

Early identification of progressive multiple sclerosis (MS) is crucial for timely treatment. This review examines current and future methods for predicting MS progression, including new biomarkers and expanded assessment criteria.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K

Related Experiment Videos

Last Updated: Dec 19, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K

Area of Science:

  • Neurology
  • Neuroimmunology
  • Clinical Medicine

Background:

  • Multiple sclerosis (MS) progression is often identified retrospectively.
  • Effective treatments for progressive MS necessitate early detection.
  • Current diagnostic methods lack early predictive capabilities for MS progression.

Purpose of the Study:

  • To review current measures for predicting progressive multiple sclerosis (MS).
  • To discuss emerging biomarkers for understanding MS progression mechanisms.
  • To consider expanding the definition of progressive MS to include cognition, patient-reported outcomes, and comorbidities.

Main Methods:

  • Literature review of pathological findings and predictive measures for MS progression.
  • Assessment of the current state-of-the-art in identifying progressive MS.
  • Discussion of potential future biomarkers and expanded diagnostic concepts.

Main Results:

  • Current methods for identifying MS progression are primarily retrospective.
  • Several potential biomarkers and assessment strategies show promise for early prediction.
  • Expanding the concept of progressive MS is essential for comprehensive patient care.

Conclusions:

  • There is an urgent need for early identification measures for progressive multiple sclerosis.
  • Future research should focus on validating novel biomarkers and integrated assessment approaches.
  • A broader definition of progressive MS, incorporating cognitive and patient-reported outcomes, is recommended.